Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Aims $500 Million Sales For Prasugrel By 2013

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo has established a priority for blood thinning agent Effient (prasugrel) and set a global sales goal of $500 million in three years. Launched last year in the U.S. and Europe, the potential blockbuster antiplatelet agent is co-promoted with Eli Lilly. Daiichi President Takashi Shoda disclosed that the two are exploring ways to further marketing efforts. Daiichi recently revealed a three-year mid-term business strategy, in which it plans to focus resources on expanding market shares for prasugrel, hoping to grow it as the first-in-class oral antiplatelet treatment. Meanwhile, for another potential oral Xa factor inhibitor DU-176b (edoxaban), Daiichi has decided to first launch it in the domestic market. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC074344

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel